New trial aims to stop thymic cancer recurrence with combined treatment
NCT ID NCT06402708
First seen Apr 30, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This phase 3 trial tests whether adding chemotherapy to standard radiotherapy after complete surgical removal of thymic cancer can reduce the chance of the cancer coming back. About 172 adults aged 18-75 with early-stage thymic cancer will be randomly assigned to receive either radiotherapy alone or radiotherapy plus four cycles of chemotherapy (paclitaxel, cisplatin, 5-FU). Participants will be followed for at least two years to track cancer recurrence and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 212013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel, cisplatin, 5-FU, and calcium folinate (chemotherapy drugs) plus radiotherapy
What this could lead to
If successful, this could show that adding chemotherapy after surgery helps prevent thymic cancer from coming back.
What could go wrong
This is a mid-stage trial with only 172 people, so results may not apply to everyone. Chemotherapy can cause side effects like low blood counts and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.